Florokinolonların Etki Spektrumu ve Kullanım Alanları
Özet
Florokinolonlar sentetik bakterisidal bir antibiyotik grubudur. Doku dağılımları ve oral biyoyararlanımları yüksektir. Kinolonların ilk üyesi nalidiksik asittir. Bu antibiyotiklerbakterilerdeki DNA giraz ve topoizomeraz IV enzimatik aktivitelerini inhibe etmektedir. Özellikle Enterik veHaemophilus spp. gibi Gram negatif basillere , Neisseria spp., Moraxella catarrhalis gibi Gram negatif koklara, ayrıca P.aeruginosa ve stafilokoklara karşı da etkilidir. Kinolonlar içerisinde siprofloksasin Gram negatif etkinliği en yüksek ve P.aeruginosa etkinliği olan en güçlü olandır.Kinolonların üriner sistem enfeksiyonu, prostatit, gastroenterit, solunum yolu enfeksiyonu, kemik-eklem enfeksiyonu, yumuşak doku enfeksiyonu, mikobakteri enfeksiyonları, şarbon, tularemi, enterik tifo/paratifo gibi enfeksiyonlarda kullanım alanı mevcuttur.
Referanslar
Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases Ninth Edition.Quinolones; 426-448.
Wang JC. DNA topoisomerases. Annu Rev Biochem. 1996;65:635–692.
Ullsperger C, Cozzarelli NR. Contrasting enzymatic activities of topoisomerase IV and DNA gyrase from Escherichia coli. J Biol Chem. 1996;271: 31549–31555.
Kohanski MA, Dwyer DJ, Hayete B, et al. A common mechanism of cellular death induced by bactericidal antibiotics. Cell. 2007;130:797–810.
Eliopoulos CT, Eliopoulos GM. Activity in vitro of the quinolones. In: Hooper DC, Rubinstein E, eds. Quinolone Antimicrobial Agents. Washington, DC: American Society for Microbiology Press; 2003:91–111.
Eliopoulos GM, Eliopoulos CT. Activity in vitro of the quinolones. In: Hooper DC, Wolfson JS, eds. Quinolone Antimicrobial Agents. Washington, DC: American Society for Microbiology; 1993:161–193.
Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev. 1989;2:378–424.
Jones RN, Fritsche TR, Sader HS. Antimicrobial activity of DC-159a, a new fluoroquinolone, against 1,149 recently collected clinical isolates. Antimicrob Agents Chemother. 2008;52:3763–3775.
Aldred KJ, McPherson SA, Wang P, et al. Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance. Biochemistry. 2012;51:370–381.
Dudley MN. Pharmacokinetics of fluoroquinolones. In: Hooper DC, Rubinstein E, eds. Quinolone Antimicrobial Agents. Washington, DC: American Society for Microbiology Press; 2003:115–132.
Lode H, Hoffken G, Boeckk M, et al. Quinolone pharmacokinetics and metabolism. J Antimicrob Chemother. 1990;26(supplB):41–49.
Nau R, Sorgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010;23:858–883.
Raz R, Chazan B, Kennes Y, et al. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis. 2002;34:1165–1169.
Manges AR, Johnson JR, Foxman B, et al. Widespread distribution of urinary tract infections caused by a multidrug-resistant Escherichia coli clonal group. N Engl J Med. 2001;345:1007–1013.
Sabbaj J, Hoagland VL, Cook T. Norfloxacin versus co-trimoxazole in the treatment of recurring urinary tract infections in men. Scand J Infect Dis. 1986;48:48–53.
Hooper DC, Wolfson JS. Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects. Antimicrob Agents Chemother. 1989;33:1662–1667.
Thorpe EM, Schwebke JR, Hook EW, et al. Comparison of single-dose cefuroxime axetil with ciprofloxacin in treatment of uncomplicated gonorrhea caused by penicillinase-producing and non-penicillinase-producing Neisseria gonorrhoeae strains. Antimicrob Agents Chemother. 1996;40:2775–2780.
Peeling RW, Ronald AR. Use of quinolones for treatment of sexually transmitted diseases. In: Hooper DC, Rubinstein E, eds. Quinolone Antimicrobial Agents. Washington, DC: American Society for Microbiology Press; 2003:171–192.
Kitchen VS, Donegan C, Ward H, et al. Comparison of ofloxacin with doxycycline in the treatment of non-gonococcal urethritis and cervical chlamydial infection. J Antimicrob Chemother. 1990;26(supplD):99–105.
Mikamo H, Sato Y, Hayasaki Y, et al. Adequate levofloxacin treatment schedules for uterine cervicitis caused by Chlamydia trachomatis. Chemotherapy. 2000;46:150–152.
Bennish ML. Treatment and prophylaxis of gastroenteritis. In: Hooper DC, Rubinstein E, eds. Quinolone Antimicrobial Agents. Washington, DC: American Society for Microbiology Press; 2003:193–216.
Wiström J, Jertborn M, Hedstrom SA, et al. Short-term self-treatment of travellers’ diarrhoea with norfloxacin: a placebo-controlled study. J Antimicrob Chemother. 1989;23:905–913.
Ericsson CD, Johnson PC, DuPont HL, et al. Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers’ diarrhea. A placebo-controlled, randomized trial. Ann Intern Med. 1987;106:216–220
Ott SR, Allewelt M, Lorenz J, et al. Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess. Infection. 2008;36:23–30
Gentry LO. Oral antimicrobial therapy for osteomyelitis. Ann Intern Med. 1991;114:986–987.
Pullman J, Gardovskis J, Farley B, et al. Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a phase 3, double-blind, randomized study. J Antimicrob Chemother. 2017;72:3471–3480
Johnson JL, Hadad DJ, Boom WH, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2006;10:605–612.
de Lalla F, Maserati R, Scarpellini P, et al. Clarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS. Antimicrob Agents Chemother. 1992;36:1567–1569
Kemper CA, Meng TC, Nussbaum J, et al. Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen. Rifampin, ethambutol, clofazimine, and ciprofloxacin. The california collaborative treatment group. Ann Intern Med. 1992;116:466–472.
